Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo- controlled, double-blind, randomized trial Tasuku Harada, M.D., Mikio Momoeda, M.D. Fertility and Sterility Volume 106, Issue 7, Pages 1807-1814 (December 2016) DOI: 10.1016/j.fertnstert.2016.08.051 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Flow diagram of the randomized, controlled trial. Fertility and Sterility 2016 106, 1807-1814DOI: (10.1016/j.fertnstert.2016.08.051) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Figure 2 Changes in the mean (±SE) dysmenorrhea and VAS scores from the pretreatment cycle to cycle 5 in the patients with (A) dysmenorrhea, (B) primary dysmenorrhea, and (C) secondary dysmenorrhea. *P<.05, **P<.01 for NPC-01 vs. placebo. Fertility and Sterility 2016 106, 1807-1814DOI: (10.1016/j.fertnstert.2016.08.051) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Figure 3 Changes in the incidence rate of irregular uterine bleeding (not spotting) from the first treatment cycle to the fourth treatment cycle. Fertility and Sterility 2016 106, 1807-1814DOI: (10.1016/j.fertnstert.2016.08.051) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions